- Philstar.com
- The Philippine Star
- Pilipino Star Ngayon
- The Freeman
- Pang-Masa
- Banat
- Interaksyon
- Coupons
SUPPORT PHILSTAR
About Us |
Contact Us |
Advertise |
Privacy Policy |
Member Agreement |
Copyright Notice
Copyright © 2024. Philstar Global Corp. All Rights Reserved
X
+ Follow RECEPTOR Tag
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 359180 [Title] => Antibody vs antibody [Summary] => Antibodies protect us from parasites, germs, toxins, and other foreign substances (antigens) that may enter our body. Binding of antibodies to an antigen causes the neutralization of the substance, its immobilization and increased susceptibility to elimination by natural processes, or death in the case of an invading cell. Antibodies can be produced against virtually any foreign substance actually, against any accessible part of the antigen and biotechnology allows us to produce virtually unlimited amounts of any antibody whose properties we desire. [DatePublished] => 2006-09-21 00:00:00 [ColumnID] => 135735 [Focus] => 0 [AuthorID] => 1754920 [AuthorName] => STAR SCIENCE By Eduardo A. Padlan, Ph.D. [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 186110 [Title] => Key estrogen receptor gene mutation discovered [Summary] => A mutant gene that makes estrogen receptors hypersensitive has been identified and it may play an important role in the evolution of invasive breast cancer, investigators reported at the annual breast cancer symposium sponsored by the San Antonio Cancer Institute.
[DatePublished] => 2002-12-01 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [2] => Array ( [ArticleID] => 140669 [Title] => Cardiovascular study underway [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Associations annual meeting its extensive cardiovascular trial program ONTARGET.
The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan.
Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies.
[DatePublished] => 2001-11-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
RECEPTOR
Array ( [results] => Array ( [0] => Array ( [ArticleID] => 359180 [Title] => Antibody vs antibody [Summary] => Antibodies protect us from parasites, germs, toxins, and other foreign substances (antigens) that may enter our body. Binding of antibodies to an antigen causes the neutralization of the substance, its immobilization and increased susceptibility to elimination by natural processes, or death in the case of an invading cell. Antibodies can be produced against virtually any foreign substance actually, against any accessible part of the antigen and biotechnology allows us to produce virtually unlimited amounts of any antibody whose properties we desire. [DatePublished] => 2006-09-21 00:00:00 [ColumnID] => 135735 [Focus] => 0 [AuthorID] => 1754920 [AuthorName] => STAR SCIENCE By Eduardo A. Padlan, Ph.D. [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 186110 [Title] => Key estrogen receptor gene mutation discovered [Summary] => A mutant gene that makes estrogen receptors hypersensitive has been identified and it may play an important role in the evolution of invasive breast cancer, investigators reported at the annual breast cancer symposium sponsored by the San Antonio Cancer Institute.
[DatePublished] => 2002-12-01 00:00:00 [ColumnID] => 136231 [Focus] => 0 [AuthorID] => 1805110 [AuthorName] => Charles C. Chante MD [SectionName] => Opinion [SectionUrl] => opinion [URL] => ) [2] => Array ( [ArticleID] => 140669 [Title] => Cardiovascular study underway [Summary] => The pharmaceutical company Boehringer Ingelheim has presented before the American Heart Associations annual meeting its extensive cardiovascular trial program ONTARGET.
The program will investigate the additional potential of newer blood pressure-reducing medications called angiotensin II receptor blocker such as telmisartan.
Boehringer Ingelheim will also be conducting 10 additional cardiovascular studies.
[DatePublished] => 2001-11-19 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
By STAR SCIENCE By Eduardo A. Padlan, Ph.D. | September 21, 2006 - 12:00am
By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | December 1, 2002 - 12:00am
November 19, 2001 - 12:00am
Recommended
Fired up by its 114-112 steal in Game 3, Converge sprang another ambush on mighty San Miguel Beer.
17 hours ago
White confetti fell and the University of Santo Tomas Tigresses had all the time to celebrate.
17 hours ago
Regional players turned in commanding performances in the ICTSI Junior PGT National Match Play Finals, capturing six of the eight titles disputed at The Country Club here on Friday.
17 hours ago
Arellano University added another big fish to its growing NCAA Season 100 catch after it shocked leader St. Benilde, 73-71, yesterday to light up its flickering Final Four hopes at the Filoil EcoOil Arena.
17 hours ago
The Philippine men’s and women’s football teams are gearing up for testy battles overseas as part of their respective preparations for major competitions down the road.
17 hours ago
Lotto Oct 4, 2024
EZ2/LVM - 14 16
SUERTRES - 8 3 2
6D Lotto - 9 0 3 0
6/45 Lotto - 41 44 23 3 17 5
P94,470,811.00
6/58 Ultra Lotto - 46 19 11 40 41 16
P228,127,654.00
Forex
February 12, 2018
- 12:00 am
- 12:00 am
1$ : P51.66